These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37313640)

  • 1. Diphenylcyclopropenone and platelet-rich plasma in the management of severe or recalcitrant alopecia areata.
    Abd El-Magid WM; Mohamed RA; Elsharkawy RE
    J Cosmet Dermatol; 2023 Nov; 22(11):2971-2981. PubMed ID: 37313640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
    Ghandi N; Daneshmand R; Hatami P; Abedini R; Nasimi M; Aryanian Z; Vance TM
    Int Immunopharmacol; 2021 Oct; 99():107971. PubMed ID: 34298402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
    Durdu M; Özcan D; Baba M; Seçkin D
    J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response?
    Ghandi N; Seifi G; Nasimi M; Abedini R; Mirabedian S; Etesami I; Ehsani A
    Dermatol Ther; 2021 Nov; 34(6):e15118. PubMed ID: 34464020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
    Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H
    Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata.
    Sriphojanart T; Khunkhet S; Suchonwanit P
    Dermatol Reports; 2017 Oct; 9(2):7399. PubMed ID: 29299216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata.
    Al Bazzal A; Hatami P; Abedini R; Etesami I; Ayanian Z; Ghandi N
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108186. PubMed ID: 34710658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
    Aghaei S
    BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens.
    Nowicka D; Maj J; Jankowska-Konsur A; Hryncewicz-Gwóźdź A
    Postepy Dermatol Alergol; 2018 Dec; 35(6):577-581. PubMed ID: 30618524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
    Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
    Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial to compare the effectiveness and safety of low dose dexamethasone oral mini-pulse versus diphenylcyclopropenone contact sensitisation in severe pediatric alopecia areata.
    Mahajan R; Daroach M; Handa S; De D
    Dermatol Ther; 2022 Nov; 35(11):e15810. PubMed ID: 36086930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation.
    Shapiro J; Tan J; Ho V; Abbott F; Tron V
    J Am Acad Dermatol; 1993 Nov; 29(5 Pt 1):729-35. PubMed ID: 7901248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
    Ibrahim SA; Esawy AM; Abdelshafy AS
    Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
    Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X
    Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
    Kagami S; Kishi Y; Hino H
    J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.
    Cotellessa C; Peris K; Caracciolo E; Mordenti C; Chimenti S
    J Am Acad Dermatol; 2001 Jan; 44(1):73-6. PubMed ID: 11148480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata.
    Lekhavat C; Rattanaumpawan P; Juengsamranphong I
    Skin Appendage Disord; 2022 Mar; 8(2):108-117. PubMed ID: 35419425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: Retrospective analysis of 159 cases.
    Choe SJ; Lee S; Pi LQ; Keum DI; Lee CH; Kim BJ; Lee WS
    J Am Acad Dermatol; 2018 Mar; 78(3):515-521.e4. PubMed ID: 29108907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can the Cytokine Analysis of the Scales on Alopecic Patch Predict the Response to Diphenylcyclopropenone Treatment in Alopecia Areata Patients?
    Lee SH; Moon JH; Ban DH; Byun JW; Shin J; Choi GS
    Ann Dermatol; 2018 Apr; 30(2):150-157. PubMed ID: 29606811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diphenylcyclopropenone plays an effective therapeutic role by up-regulating the TSLP/OX40L/IL-13 pathway in severe alopecia areata.
    Gong Y; Luo L; Li L; He X; Lu W; Sha X; Mao Y
    Exp Dermatol; 2021 Feb; 30(2):278-283. PubMed ID: 33325128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.